These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34748565)

  • 1. Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus.
    Das L; Rastogi A; Jude EB; Prakash M; Dutta P; Bhansali A
    PLoS One; 2021; 16(11):e0259224. PubMed ID: 34748565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.
    Jude EB; Selby PL; Burgess J; Lilleystone P; Mawer EB; Page SR; Donohoe M; Foster AV; Edmonds ME; Boulton AJ
    Diabetologia; 2001 Nov; 44(11):2032-7. PubMed ID: 11719835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of bone metabolism and developments in medical treatment of the diabetic Charcot foot.
    Jansen RB; Svendsen OL
    J Diabetes Complications; 2018 Jul; 32(7):708-712. PubMed ID: 29857955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of medical treatment for Charcot neuroarthropathy: a systematic review and meta-analysis of randomized controlled trials.
    Rastogi A; Bhansali A; Jude EB
    Acta Diabetol; 2021 Jun; 58(6):687-696. PubMed ID: 33439331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diabetic Charcot foot.
    Dissanayake SU; Bowling FL; Jude EB
    Curr Diabetes Rev; 2012 May; 8(3):191-4. PubMed ID: 22429012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriparatide (recombinant human parathyroid hormone [1-34]) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double-blind placebo-controlled study.
    Rastogi A; Hajela A; Prakash M; Khandelwal N; Kumar R; Bhattacharya A; Mittal BR; Bhansali A; Armstrong DG
    J Diabetes; 2019 Sep; 11(9):703-710. PubMed ID: 30632290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent inflammation with pedal osteolysis 1year after Charcot neuropathic osteoarthropathy.
    Sinacore DR; Bohnert KL; Smith KE; Hastings MK; Commean PK; Gutekunst DJ; Johnson JE; Prior FW
    J Diabetes Complications; 2017 Jun; 31(6):1014-1020. PubMed ID: 28254346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors of charcot neuroarthropathy development in patients with type 2 diabetes.
    Nehring P; Mrozikiewicz-Rakowska B; Maroszek P; Sobczyk-Kopcioł A; Krzyżewska M; Płoski R; Karnafel W
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):31-4. PubMed ID: 24203651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study.
    Jansen RB; Christensen TM; Bülow J; Rørdam L; Holstein PE; Jørgensen NR; Svendsen OL
    J Diabetes Complications; 2018 Feb; 32(2):164-170. PubMed ID: 29196119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome after protected full weightbearing treatment in an orthopedic device in diabetic neuropathic arthropathy (Charcot arthropathy): a comparison of unilaterally and bilaterally affected patients.
    Renner N; Wirth SH; Osterhoff G; Böni T; Berli M
    BMC Musculoskelet Disord; 2016 Dec; 17(1):504. PubMed ID: 28031030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial.
    Pakarinen TK; Laine HJ; Mäenpää H; Mattila P; Lahtela J
    Diabetes Care; 2011 Jul; 34(7):1514-6. PubMed ID: 21593295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early development of Charcot neuroarthropathy in the course of compensated diabetes mellitus--case report].
    Kamińska A; Kamiński M; Jesionka P; Szymkowiak E; Bronisz A; Zmudzińska M; Junik R; Sikorska Z
    Pol Arch Med Wewn; 2004 Jun; 111(6):709-13. PubMed ID: 15508794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies to post-translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus.
    Rizzo P; Pitocco D; Zaccardi F; Di Stasio E; Strollo R; Rizzi A; Scavone G; Costantini F; Galli M; Tinelli G; Flex A; Caputo S; Pozzilli P; Landolfi R; Ghirlanda G; Nissim A
    Diabetes Metab Res Rev; 2017 Feb; 33(2):. PubMed ID: 27454862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Charcot arthropathy in patients with diabetes mellitus: healing times by foot location.
    Sinacore DR
    J Diabetes Complications; 1998; 12(5):287-93. PubMed ID: 9747646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arthrodesis as an early alternative to nonoperative management of charcot arthropathy of the diabetic foot.
    Simon SR; Tejwani SG; Wilson DL; Santner TJ; Denniston NL
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):939-50. PubMed ID: 10901308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Charcot arthropathy successfully treated with pamidronate: long-term follow-up.
    Naqvi A; Cuchacovich R; Saketkoo L; Espinoza LR
    Am J Med Sci; 2008 Feb; 335(2):145-8. PubMed ID: 18277124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory osteolysis in diabetic neuropathic (charcot) arthropathies of the foot.
    Sinacore DR; Hastings MK; Bohnert KL; Fielder FA; Villareal DT; Blair VP; Johnson JE
    Phys Ther; 2008 Nov; 88(11):1399-407. PubMed ID: 18801857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy?
    Selby PL; Young MJ; Boulton AJ
    Diabet Med; 1994; 11(1):28-31. PubMed ID: 8181248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hot foot: Charcot neuroarthropathy or osteomyelitis? Untangling a diagnostic web.
    Goldsmith L; Barlow M; Evans PJ; Srinivas-Shankar U
    BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31088814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for Charcot foot.
    Nóbrega MB; Aras R; Netto EM; Couto RD; Marinho AM; da Silva JL; Colares VN; Campelo PL; Nunes MA
    Arch Endocrinol Metab; 2015 Jun; 59(3):226-30. PubMed ID: 26154090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.